-
Morgan Stanley Discontinuations 7/6 Continued
Thursday, July 7, 2011 - 7:19am | 103Morgan Stanley has discontinued coverage on the following companies: Affymetrix (NASDAQ: AFFY) Pacific Biosciences (NASDAQ: PACB) Gen-Probe (NASDAQ: GPRO) Thermo Fisher Scientific (NYSE: TMO) Myriad Genetics (NASDAQ: MYGN) Waters Corporation (NYSE: WAT) Ilumina (NASDAQ: ILMN) Life Technology (...
-
Phase 3 Trial of ZALTRAP in Advanced Prostate Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
Thursday, July 7, 2011 - 7:05am | 145Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 3 VENICE clinical trial evaluating the investigational agent ZALTRAP™ (aflibercept) in the first-line treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer will continue to...
-
LifeTech Capital Raises StemCells PT to $8, Maintains Strong Speculative Buy
Wednesday, July 6, 2011 - 12:09pm | 81LifeTech Capital raised its StemCells (NASDAQ: STEM) (NASDAQ: STEMD) price target from $1.60 to $8 and maintained its Strong Speculative Buy rating in a research report published today. In the report, LifeTech Capital states, "StemCells Inc. executed a 1:10 reverse split on July 6th and will trade...
-
Biotech/Pharma Stocks Investor News Alert
Wednesday, July 6, 2011 - 10:52am | 1385Point Roberts, WA - July 6, 2011 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for July 5, 2011. The NASDAQ Biotech Stock Index closed at 1,123.61, up 3.05. The AMEX Biotech Index (^BTK) closed up at 1,...
-
Goldman Sachs Downgrades Cepheid On Outperformance
Wednesday, July 6, 2011 - 8:57am | 144Goldman Sachs is downgrading shares of Cepheid (NASDAQ: CPHD) to Neutral on outperformance. It has a $35 price target on shares. In a note to clients, Goldman Sachs writes, "We are downgrading Cepheid (CPHD) shares to Neutral from Buy following the stock's outperformance vs. the peer group and...
-
Synta Announces Presentation of Small Cell Lung Cancer Results; Synta's Ganetespib More Potent Than 17-AAG
Wednesday, July 6, 2011 - 8:35am | 94Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that results presented at the International Association for the Study of Lung Cancer 14th World Conference on Lung Cancer showed that ganetespib is more potent than 17-AAG and is synergistic with doxorubicin in a model of small cell lung...
-
CytRx Announces Safe Administration of High Doses of Doxorubicin with Its Tumor-Targeted Drug, INNO-206
Wednesday, July 6, 2011 - 8:31am | 65CytRx Corporation (Nasdaq: CYTR) today announced that its tumor-targeted doxorubicin conjugate, INNO-206, is delivering doxorubicin safely at doses over 4 times higher than the standard doxorubicin dose in the Company's open-label Phase 1b safety and dose escalation clinical trial. The clinical...
-
Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
Wednesday, July 6, 2011 - 8:31am | 360- FDA Approves Los Angeles Immunotherapy Manufacturing Facility, CMS Announces National Coverage Decision, and Product Specific Q-Code Effective Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the...
-
Benzinga's Top Downgrades
Wednesday, July 6, 2011 - 8:17am | 132Analysts at Morgan Stanley downgraded WPP plc (NASDAQ: WPPGY) from “overweight” to “equal-weight.” WPP's stock closed at $62.87 yesterday. WPP's trailing-twelve-month ROA is 2.66%. Analysts at Kaufman Bros downgraded NetScout Systems Inc (NASDAQ: NTCT) from “buy” to “hold.” NTCT's shares closed at...
-
Threshold Pharmaceuticals Announces National Comprehensive Cancer Network (NCCN) Grant for Phase 1 Trial of TH-302 in Combination with Pazopanib
Wednesday, July 6, 2011 - 8:06am | 307Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), today announced that The National Comprehensive Cancer Network, a not-for-profit alliance of 21 of the world's leading cancer centers, awarded a grant to Dr. Herb Hurwitz, Associate Professor of Medicine at the Duke Cancer Institute, to evaluate...
-
Capstone Therapeutics Announces Pre-Clinical Results With AZX100 in Radiation and Bleomycin Models of Pulmonary Fibrosis; Pulmonary Anti-Fibrotic Effect Demonstrated
Wednesday, July 6, 2011 - 8:04am | 244Capstone Therapeutics (Nasdaq: CAPS) today announced results from a pre-clinical study of AZX100 in a rodent model of radiation-induced pulmonary fibrosis. Using the TUNEL assay – an established method for detecting DNA fragments that are the hallmark of "programmed cell death" known as "apoptosis...
-
Rosetta Genomics Announces 1-For-4 Reverse Stock Split
Wednesday, July 6, 2011 - 8:02am | 59Rosetta Genomics, Ltd. (NASDAQ: ROSG) today announced the effectiveness of a one-for-four reverse stock split of its share capital. The reverse stock split, which was previously approved by the Company's Board of Directors, was approved by its shareholders at the 2011 Annual General Meeting of...
-
Celldex Appoints Pepin CBO
Wednesday, July 6, 2011 - 8:01am | 54Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced the appointment of Ronald A. Pepin, Ph.D. to Senior Vice President and Chief Business Officer, effective immediately. Dr. Pepin brings to Celldex more than 20 years of business development and senior leadership experience in the...
-
Jefferies Initiates Coverage of ImmunoGen with Buy and PT of $19
Wednesday, July 6, 2011 - 7:48am | 50Jefferies initiated its coverage of ImmunoGen (NASDAQ: IMGN) with a Buy rating and a price target of $19. On Tuesday, ImmunoGen lost 1.29% of its value to end the day at $12.21. Its shares fell some more in today's pre-market trading, after edging down 0.08% to $12.20.
-
Piper Jaffray Reiterates OW Rating on Seattle Genetics
Wednesday, July 6, 2011 - 7:34am | 61“We reiterate our Overweight rating,” Piper Jaffray wrote in a report focusing on Seattle Genetics Inc. (NASDAQ: SGEN). “Our $20 price target is based on a $1.9 billion enterprise value plus YE'11E cash of $310 million. SGEN has no debt. We see upside to our target based on ADCETRIS approval.”...